Citadel Advisors’s Redhill Biopharma RDHL Stock Holding History

Citadel Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$659	–	15375
2022 Q4	$659	Buy	+5	New	+$2.17K	﹤0.01%	14606
2022 Q3	–	Sell	-10	Closed	-$9K	–	13437
2022 Q2	$9K	Sell	10 -12	-55%	-$16.5K	﹤0.01%	12606
2022 Q1	$56K	Sell	22 -25	-53%	-$59.3K	﹤0.01%	12720
2021 Q4	$120K	Sell	47 -36	-43%	-$144K	﹤0.01%	12528
2021 Q3	$379K	Sell	83 -96	-54%	-$651K	﹤0.01%	10542
2021 Q2	$1.23M	Buy	179 +12	+7%	+$82.8K	﹤0.01%	7795
2021 Q1	$1.22M	Buy	167 +157	+1,570%	+$1.32M	﹤0.01%	7598
2020 Q4	$84K	Sell	10 -7	-41%	-$62.9K	﹤0.01%	10321
2020 Q3	$173K	Sell	17 -3	-15%	-$24.6K	﹤0.01%	8919
2020 Q2	$135K	Buy	+20	New	+$138K	﹤0.01%	8812

Other funds holding RDHL

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

YAL

Your Advocates Ltd Houston, Texas $328M AUM 19.81% 1-Year Est. Return

Citadel Advisors's RDHL Position: Q1 2026 in Review

Citadel Advisors increased its Redhill Biopharma (RDHL) stake by 34% in Q1 2026, buying an estimated $5.48K and bringing the position to 20,673 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12712.

Citadel Advisors first reported a position in RDHL in Q4 2017 and has held it in 15 quarters since. The position peaked at $265K in Q4 2021. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2026.

Citadel Advisors held 20,673 shares of Redhill Biopharma worth $15.4K as of Q1 2026.
Citadel Advisors bought 5,196 Redhill Biopharma shares in Q1 2026, an estimated $5.48K.
Redhill Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12712 holding.
Citadel Advisors first reported a position in Redhill Biopharma in Q4 2017 and has held it in 15 quarters since.
Citadel Advisors's Redhill Biopharma position peaked at $265K in Q4 2021.
16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.